Bulk Manufacturer of Controlled Substances Application: AMRI Rensselaer, Inc., 95639-95640 [2016-31284]

Download as PDF Federal Register / Vol. 81, No. 249 / Wednesday, December 28, 2016 / Notices Albuquerque, New Mexico. Goff, F., and Goff, C.J., In Press (2016–17), Overview of the Valles Caldera (Baca) geothermal system, New Mexico, in (McLemore, V.T. and Timmons, S., eds.) Energy and Mineral Resources of New Mexico. New Mexico Bureau of Geology and Mineral Resources, Special Publication 13, 50 pages, with 5 tables, 1 appendix, and 40 figures. Goff, F. (2002). ‘‘Geothermal Potential of Valles Caldera, New Mexico.’’ GHC Bulletin, December 2002. Goff, F. and Grigsby, C. (1982). Valles Caldera Geothermal Systems, New Mexico, USA. Journal of Hydrology, 56 (1982) pp. 119– 136. Geologic Map of the Jemez mountains, Valles Caldera (2011). http://geoinfo.nmt.edu/ repository/data/2011/20110002/GM-79_ mapsheet.pdf. http://en.openei.org/wiki/ Valles_Caldera--Sulphur_Springs_ Geothermal_Area/#Regional Setting. Trainer, F.W.; Rogers, R.J., and M.L. Sorey, 2000. ‘‘Geothermal Hydrology of Valles Caldera and the Southwestern Jemez Mountains, New Mexico.’’ U.S. Geological Survey, Water Resources Investigation report 00–4067, 115 pp. www.hotspringsenthusiast.com/ newmexico.asp. Dated: December 19, 2016. Michael Bean, Principal Deputy Assistant Secretary, Fish and Wildlife and Parks. [FR Doc. 2016–31270 Filed 12–27–16; 8:45 am] By order of the Commission. Issued: December 22, 2016. Lisa R. Barton, Secretary to the Commission. BILLING CODE 4312–52–P INTERNATIONAL TRADE COMMISSION BILLING CODE 7020–02–P JUDICIAL CONFERENCE OF THE UNITED STATES Iron Construction Castings From Brazil, Canada, and China Hearings of the Judicial Conference Advisory Committee on the Federal Rules of Appellate Procedure Determination On the basis of the record 1 developed in the subject five-year reviews, the United States International Trade Commission (‘‘Commission’’) determines, pursuant to the Tariff Act of 1930 (‘‘the Act’’), that revocation of the countervailing duty order on heavy iron construction castings from Brazil, the antidumping duty order on heavy iron construction castings from Canada, and the antidumping duty orders on iron construction castings from Brazil and China would be likely to lead to continuation or recurrence of material injury to industries in the United States within a reasonably foreseeable time. Advisory Committee on the Federal Rules of Appellate Procedure, Judicial Conference of the United States. ACTION: Notice of cancellation of public hearing. AGENCY: The following public hearing on proposed amendments to the Federal Rules of Appellate Procedure has been canceled: Appellate Rules Hearing on January 20, 2017, in Denver, Colorado. Announcement for this meeting was previously published in 81 FR 52713. FOR FURTHER INFORMATION CONTACT: Rebecca A. Womeldorf, Rules Committee Secretary, Rules Committee SUMMARY: Support Office, Administrative Office of the United States Courts, Washington, DC 20544, telephone (202) 502–1820. Dated: December 22, 2016. Rebecca A. Womeldorf, Rules Committee Secretary. [FR Doc. 2016–31349 Filed 12–27–16; 8:45 am] BILLING CODE 2210–55–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: AMRI Rensselaer, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before February 27, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on September 26, 2016, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: [FR Doc. 2016–31335 Filed 12–27–16; 8:45 am] [Investigation Nos. 701–TA–249 and 731– TA–262, 263, and 265 (Fourth Review)] sradovich on DSK3GMQ082PROD with NOTICES Background The Commission, pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)), instituted these reviews on October 1, 2015 (80 FR 59192) and determined on January 4, 2016 that it would conduct full reviews (81 FR 1967, January 14, 2016). Notice of the scheduling of the Commission’s reviews and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register on June 23, 2016 (81 FR 40921). The hearing was held in Washington, DC, on October 20, 2016, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission made these determinations pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on December 21, 2016. The views of the Commission are contained in USITC Publication 4655 (December 2016), entitled Iron Construction Castings from Brazil, Canada, and China: Investigation Nos. 701–TA–249 and 731–TA–262, 263, and 265 (Fourth Review). 1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). VerDate Sep<11>2014 18:54 Dec 27, 2016 Jkt 241001 PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 95639 E:\FR\FM\28DEN1.SGM 28DEN1 95640 Federal Register / Vol. 81, No. 249 / Wednesday, December 28, 2016 / Notices Controlled substance Drug code Codeine ........................................................................................................................................................................... Oxycodone ....................................................................................................................................................................... Hydromorphone ............................................................................................................................................................... Hydrocodone ................................................................................................................................................................... Morphine .......................................................................................................................................................................... The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers. Dated: December 20, 2016. Louis J. Milione, Assistant Administrator. [FR Doc. 2016–31284 Filed 12–27–16; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Noramco, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on DATES: or before January 27, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before January 27, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and request for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007). The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers importers, and exporters of, controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on October 14, 2016, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as an importer of the following basic classes of controlled substances: Drug code Phenylacetone ................................................................................................................................................................. Thebaine .......................................................................................................................................................................... Poppy Straw Concentrate ............................................................................................................................................... Tapentadol ....................................................................................................................................................................... sradovich on DSK3GMQ082PROD with NOTICES [FR Doc. 2016–31281 Filed 12–27–16; 8:45 am] BILLING CODE 4410–09–P 18:54 Dec 27, 2016 [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Navinta LLC Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before February 27, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: Dated: December 19, 2016. Louis J. Milione, Assistant Administrator. VerDate Sep<11>2014 Drug Enforcement Administration ACTION: Jkt 241001 PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 8501 9333 9670 9780 Schedule II II II II The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on September 19, 2016, Navinta LLC, 1499 SUPPLEMENTARY INFORMATION: DEPARTMENT OF JUSTICE II II II II II SUPPLEMENTARY INFORMATION: Controlled substance The company plans to import thebaine derivatives (9333) as reference standards. The company plans to import an intermediate form of tapentadol (9780) to bulk manufacture tapentadol for distribution to its customers. The company plans to import phenylacetone (8501) and poppy straw concentrate (9670) to manufacture other controlled substances. 9050 9143 9150 9193 9300 Schedule E:\FR\FM\28DEN1.SGM 28DEN1

Agencies

[Federal Register Volume 81, Number 249 (Wednesday, December 28, 2016)]
[Notices]
[Pages 95639-95640]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-31284]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: AMRI 
Rensselaer, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.33(a) on or before February 27, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Deputy Assistant Administrator of the DEA Office of Diversion 
Control (``Deputy Assistant Administrator'') pursuant to section 7 of 
28 CFR part 0, appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
September 26, 2016, AMRI Rensselaer, Inc., 33 Riverside Avenue, 
Rensselaer, New York 12144 applied to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

[[Page 95640]]



------------------------------------------------------------------------
        Controlled substance            Drug code          Schedule
------------------------------------------------------------------------
Codeine............................            9050  II
Oxycodone..........................            9143  II
Hydromorphone......................            9150  II
Hydrocodone........................            9193  II
Morphine...........................            9300  II
------------------------------------------------------------------------

    The company plans to manufacture bulk controlled substances for use 
in product development and for distribution to its customers.

    Dated: December 20, 2016.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2016-31284 Filed 12-27-16; 8:45 am]
 BILLING CODE 4410-09-P